ADCT-602 is under clinical development by ADC Therapeutics and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ADCT-602’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADCT-602 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia. The therapeutic candidate is administered through intravenous route. It is an antibody drug conjugate composed of the humanized anti-human CD22 monoclonal antibody epratuzumab (hLL2) conjugated to pyrrolobenzodiazepine PBD dimer toxin. The drug candidate is developed based on pyrrolobenzodiazepine (PBD) technology. This technology enables cytotoxic agents to target antibodies using biodegradable linkers. It was also under development for non-Hodgkin lymphoma such as diffuse large B-cell lymphoma.
ADC Therapeutics overview
ADC Therapeutics, is a biotechnology company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat solid tumors and hematological cancers. It is investigating Loncastuximab Tesirine (Lonca), an ADC composed of a humanized monoclonal antibody against B-cell hematological tumors; and Camidanlumab Tesirine (Cami) for the treatment of solid tumors. It is also developing ADCT-602 drug for B-cell acute lymphoblastic leukemia; ADCT-601 targeting AXL in solid tumors; ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors; and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and acute myeloid leukemia. The company is a spin-off from Spirogen Ltd. ADC Therapeutics is headquartered in Lausanne, Switzerland.
For a complete picture of ADCT-602’s drug-specific PTSR and LoA scores, buy the report here.